Clinical TrialMay 13, 2026, 07:31 AM
BriaCell Adds Penn Medicine to Phase 3 Clinical Trial Sites
AI Summary
BriaCell Therapeutics Corp. announced the addition of Penn Medicine's Abramson Cancer Center as a clinical trial site for its ongoing pivotal Phase 3 study (Bria-ABC) evaluating Bria-IMT for advanced breast cancer. This expansion follows increased interest and enrollment momentum after the trial's inclusion in Nature Medicine. The Bria-IMT combination regimen has also received FDA Fast Track designation, highlighting its potential to address an unmet medical need.
Key Highlights
- BriaCell added Penn Medicine's Abramson Cancer Center as a clinical trial site for its pivotal Phase 3 study (Bria-ABC).
- Other recently activated sites include Indiana University, University of Virginia, Baptist Health South Florida, and SCRI Oncology Partners.
- The Phase 3 Bria-ABC study evaluates Bria-IMT in combination with an immune checkpoint inhibitor.
- The study targets advanced breast cancer patients who have not responded to prior therapies.
- Bria-IMT combination regimen received FDA Fast Track designation.
- An interim analysis of the Phase 3 study will occur after 144 patient deaths, with overall survival as the primary endpoint.